On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients who have multiple myeloma and are ineligible for transplant. On September ...
Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA pre-targeted radioimmunotherapy for relapsed non-Hodgkin lymphoma. Y-mAbs Therapeutics, Inc. announced that the first patient has ...
The manufacturing of the drug will be retained by TJ Biopharma at its site in Hangzhou, which would make felzartamab China’s ...
Teclistamab-cqyv significantly improves progression-free and overall survival in relapsed/refractory multiple myeloma, especially in patients refractory to anti-CD38 therapy and lenalidomide. The ...
A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...
In Europe, the SC formulation of daratumumab, another anti-CD38 antibody, recently received a label update that allowed ...
Y-mAbs presented preclinical PK data for CD38-SADA at the 2025 AACR Annual Meeting, supporting its cancer treatment development. Y-mAbs Therapeutics, Inc. announced the presentation of preclinical and ...
An investigational anti-CD38 monoclonal antibody (CM313) rapidly increased platelets in immune thrombocytopenia (ITP) patients to levels sufficient for preventing bleeding, a small single-arm Chinese ...
CD38 is an enzyme with NAD-depleting and intracellular signaling activity expressed on the cell surface, in intracellular compartments and in mitochondria, and is linked to inflammatory and autoimmune ...
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results